India Approves First Dengue Vaccine Qdenga for Public Protection

#GS-2 #Governance & Social Justice #Health #GS-3 #Science & Technology #Biotechnology #Current Events #National #Dengue Vaccine #CDSCO

Why in News

The **Central Drugs Standard Control Organisation (CDSCO)** has officially granted marketing authorization for **Qdenga**, making it India's first approved dengue vaccine.
This regulatory milestone arrives as India continues to experience one of the largest dengue burdens globally.
Reported dengue infections in the country have climbed nearly **11-fold** over the past **two decades**.

Unplanned urban growth and population density have significantly expanded mosquito breeding grounds in cities.
Shifting climate patterns help mosquitoes survive longer and spread infections to new geographic areas.
Developing effective dengue protection is complex because the disease is caused by **4 distinct virus serotypes**.
Earlier dengue vaccines required mandatory pre-vaccination blood testing, which complicated large-scale rollout efforts.

**Qdenga** (also designated as **TAK-003**) is a recombinant, live-attenuated tetravalent vaccine created by **Takeda GmbH** in Germany.
It uses a **dengue virus type-2 backbone** inserted with surface protein genes from the other three strains to shield against **DENV-1, DENV-2, DENV-3, and DENV-4**.
The vaccine will be imported and distributed locally across India by **M/s Takeda Biopharmaceuticals India Pvt. Ltd.**
Health authorities have approved **Qdenga** for individuals aged **4 to 60 years**, regardless of previous dengue infection history.
Unlike earlier formulations, this vaccine requires no prior antibody screening, simplifying clinical administration.
The immunization regimen consists of **two doses** of **0.5 ml** injected subcutaneously **3 months apart**.
It holds prequalification from the **World Health Organization (WHO)** and approval in over **40 countries**, including the European Union and the UK.
Over **24 million to 32 million doses** of **Qdenga** have already been administered across global jurisdictions.
A successful **Phase III trial** in India confirmed high immunogenicity and safety across diverse local populations.

Dengue is a viral tropical disease caused by the dengue virus, which belongs to the genus **Flavivirus**.
The infection spreads to humans through the bites of infected female mosquitoes, primarily **Aedes aegypti**.
The same **Aedes** mosquito vectors are also responsible for transmitting **chikungunya**, yellow fever, and **Zika**.
Typical symptoms include high fever, severe headache, pain behind the eyes, and severe muscle, joint, and bone pain.
According to the **World Health Organization (WHO)**, an estimated **39 crore** infections occur globally each year, with **9.6 crore** manifesting clinical symptoms.

The **CDSCO** serves as India's national regulatory authority for pharmaceuticals, medical devices, and cosmetics under the **Ministry of Health and Family Welfare**.
Headquartered in **New Delhi**, the agency operates under the **Directorate General of Health Services**.
It derives statutory powers from the **Drugs and Cosmetics Act, 1940** and the **Drugs Rules, 1945**.
The regulator evaluates the quality, safety, and efficacy of new medical products before granting market access.
It oversees clinical trial safety, regulates foreign drug imports, and coordinates with state authorities to curb substandard medicines.